---
document_datetime: 2023-12-04 14:24:38
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_en.pdf
document_name: covid-19-vaccine-inactivated-adjuvanted-valneva-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.7040289
conversion_datetime: 2025-12-31 03:30:30.514674
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name                                    | Strength   | Pharmaceutical Form      | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                      |
|------------------|----------------------------------------------------|------------|--------------------------|---------------------------|-----------------------|---------------------------|--------------------------------|
| EU/1/21/1624/001 | COVID-19 Vaccine (inactivated, adjuvanted) Valneva | --ยน        | Suspension for injection | Intramuscular use         | vial (glass)          | 5 ml (10 doses)           | 10 multidose vials (100 doses) |

--ยน

--ยน

One dose (0.5 mL) contains 33 Antigen Units (AU) of inactivated SARS-CoV-2 virus 1,2,3 .

1 Strain hCoV-19/Italy/INMI1-isl/2020 2 Produced on Vero cells (African green monkey cells) 3 Adsorbed on aluminium hydroxide (0.5 mg Al 3+  in total) and adjuvanted by 1 mg CpG 1018 (cytosine phospho-guanine) in total. Medicinal product no longer authorised